



Neuren Pharmaceuticals Limited
Level 2, 57 Wellington Street
Freemans Bay, Auckland, New Zealand
office: +64 9 3700 200
fax: +64 9 361 7981
enquiries@neurenpharma.com
www.neurenpharma.com

21 July 2011

The Company Announcements Office
ASX Limited

Change in Director's Interests Notice

In relation to the Appendix 3Y lodged earlier today relating to Mr Trevor Donald Scott, please find attached an amended Appendix 3Y that now includes the completed "Part 3 - Closed period" of the Appendix.

Yours sincerely

A handwritten signature in black ink, appearing to read "Rob Turnbull".

Rob Turnbull
Chief Financial Officer

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Neuren Pharmaceuticals Limited
ARBN:	111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Trevor Donald Scott
Date of last notice	23 December 2009

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect interests
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1. Director of Centralo Limited 2. Trustee of the TD Scott No.2 Trust 3. Essex Castle Limited as nominee custodian
Date of change	19 July 2011
No. of securities held prior to change	16,694,126 Ordinary Shares and 10,604,991 Unlisted Options with an exercise price of A\$0.0457 per option.
Class	Ordinary Shares
Number acquired	16,694,126 Ordinary Shares pursuant to the rights issue.
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	NZ\$0.017 per Ordinary Share in cash.
No. of securities held after change	33,388,252 Ordinary Shares and 10,604,991 Unlisted Options with an exercise price of A\$0.0457 per option.

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of securities applied for under 1:1 pro rata rights issue.
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No, acceptance of a rights issue offer is excluded from the Company's Securities Trading Policy.
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.